Tesla update

According to Tech Viral: “Tesla has abruptly stopped Cybertruck and Model Y production, triggering a nearly 3% stock drop to $348.29, as shown in the finance card above.

“The pause, Tesla’s third Cybertruck halt this year at its Austin Gigafactory, compounds delays in Robotaxi plans and Elon Musk’s controversies.

 

“As EV competition intensifies, Tesla’s frequent disruptions fuel doubts about its ability to meet bold goals, raising concerns among investors and customers.”

Tesla stock has been on an upward slope since January 2023. Its P/E is 178. Tesla continues to defy gravity.

 

Comments

Post a Comment

Popular posts from this blog

The ruble is collapsing

In 1998, I traveled to Moscow for the first time to teach in a summer course at the Russian Academy. The week before, we were on vacation and I heard on the radio “Today, the ruble lost 100% of its value.” This news was arresting—it meant that the ruble was worthless. That seemed unlikely. Indeed, the next day, the announcer apologized and said she meant to say that the ruble lost 50% of its value.  In the event, by the time I arrived at the Hotel Sputnik in Moscow, all the cash machines in the city were shut down. Restaurant prices changed hourly during my five-day stay, and there were sidewalk signs posting exchange rates that were written in chalk so they could easily be edited. Certainly puts our recent experience with inflation in perspective.   Over at jabberwocking.com, Kevin Drum notes that the ruble is down 30% since the war started and 20% just since September.   From the comment thread: “The problem with the Russian economy at this point is that it is basically...
Read more

Saving Ryan

I just finished reading “Saving Ryan” by Emil Kakkis. Kakkis is a physician who pioneered enzyme replacement therapy for Mucopolysaccharidosis I (MPS I), a progressive and fatal disease. The story is about the patients and their families who struggle with the disease and Emil’s struggle to deliver life-enhancing therapy against terribly long odds. The Ryan of the book’s title is a kid with MPS I. His working class parents were not content to watch Ryan decline and die in his first or second decade. MPS I is an extremely rare disease, so big pharma sees no potential for return on investment for developing treatments or cures. Ryan’s parents start a foundation to raise money for a cure. I seldom read lay science/medical books because they usually spend too much time explaining technical details that I already understand, and I find myself wincing at the imprecision and outright errors. This book avoids that pitfall, both by being scientifically sound and concise, and by keeping the f...
Read more

The price of Trump’s war on universities

  For decades, the United States has been the world leader in scientific research. Even as China has been catching up, the US has managed to remain a magnet for scientists world-wide, and its universities are the most desirable destinations for undergrads and graduate students. Until now. “ There are significant economic consequences to spiking medical research in the universities: this subsidizes the training of people who will work in the industry, and it drives the types of blue sky research that industry doesn’t want to do, but that it benefits greatly from. It creates a vacuum that other countries will rush to fill. If it persists, the comparative advantage that the US has gained by attracting top global talent will collapse.     “At the same time, what Trump and his cronies are doing to the education system with their anti-science agenda will pretty much guarantee that home grown talent is likely to be non-competitive globally. As the split with Musk over visas indi...
Read more